ATR
BuyFull HouseFLAGAptarGroup, Inc. · Healthcare · United States · $8.5B · Avg Vol: $52M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Eligible on the quant gate (Q61/V53/M50, corroborated by active buyback (1 filing days)) but blocked by nameable adverse evidence: net insider selling 0.04% of listed shares in 90d. Held at FLAG rather than REMOVE: the evidence is a caution, not a thesis-breaking event.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT APTARGROUP, INC.
Read
AptarGroup designs and manufactures innovative dispensing, sealing, and active packaging solutions for beauty, personal care, pharma, and food & beverage markets. It benefits from extensive intellectual property, advanced manufacturing capabilities, and long-standing relationships with leading global brands. The company is a global leader in value-added dispensing and active packaging, serving critical functions from product preservation to precise drug delivery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.3B | 3.5B | 3.6B | 3.8B | 4.4% | 3.9B | 4.0B | 4.1B | 4.7% |
| EPS | 3.66 | 4.34 | 5.65 | 5.97 | 17.7% | 5.53 | 5.74 | 6.57 | 4.9% |
| Shares | 65.2M | 65.9M | 66.5M | 64.2M | -1.5% | 63.6M | — | — | — |
| Debt | 1.2B | 1.2B | 1.1B | 1.5B | 7.9% | 1.4B | — | — | — |
| Equity | 2.1B | 2.3B | 2.5B | 2.7B | 9.1% | — | — | — | — |
| Op CF | 478.6M | 575.2M | 643.4M | 570.0M | 6.0% | 583.5M | — | — | — |
| Inv CF | -295.6M | -324.5M | -396.7M | -331.4M | — | — | — | — | — |
| Fin CF | -162.1M | -171.6M | -225.3M | -77.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATR | AptarGroup, Inc.(you) | $8.5B | 74 | Buy |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| TFX | Teleflex Incorporated | $5.9B | 66 | Buy |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
| ALGN | Align Technology, Inc. | $11.2B | 85 | Strong Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| WST | West Pharmaceutical Services, Inc. | $23.7B | 74 | Buy |
| SOLV | Solventum Corporation | $15.5B | 83 | Strong Buy |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
Peer medians: ROE -31.0% · P/E 25.2x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.